AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
33. B-Cell Depleting Therapies and COVID-19
ACR on Air
The Impact of Medication on Immune Response to COVID, Influenza, and Other Vaccines
The NIAID ACV-01 trial is looking at additional dose responses, both in B-cell depleted people, but also people either on Method Rexy, or mycophanaly. There are a lot of people developing vaccines that are intranasally delivered, but most of these are live attenuated and we probably can't use for the immunosuppressed. The idea about mucosal immunity is the next thing I think about. And I think the third thing is going to be, you know, impact the Immunosuppression and durability of antibody responses.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode